Metabolism Pathways of Major Therapeutics for Treating Monkeypox Mono- and Co-infection with Human Immunodeficient Virus or SARS-CoV-2

Antunes, F.; Cordeiro, R.; Virgolino, A. Monkeypox: From a neglected tropical disease to a public health threat. Infect. Dis. Rep., 2022, 14(5), 772-783.
[http://dx.doi.org/10.3390/idr14050079] [PMID: 36286200]

Huggett, J.F.; French, D.; O’Sullivan, D.M.; Moran-Gilad, J.; Zumla, A. Monkeypox: Another test for PCR. Euro Surveill., 2022, 27(32), 2200497.
[http://dx.doi.org/10.2807/1560-7917.ES.2022.27.32.2200497] [PMID: 35959687]

Mpox (monkeypox) outbreak 2022.https://www.who.int/emergencies/situations/monkeypox-oubreak-2022

Nuzzo, J.B.; Borio, L.L.; Gostin, L.O. The WHO declaration of monkeypox as a global public health emergency. JAMA, 2022, 328(7), 615-617.
[http://dx.doi.org/10.1001/jama.2022.12513] [PMID: 35895041]

Biden-Harris administration bolsters monkeypox response. 2022. Available from: https://www.hhs.gov/about/news/2022/08/04/biden-harris-administration-bolsters-monkeypox-response-hhs-secretary-becerra-declares-public-health-emergency.

Choi, J. Most patients hospitalized for monkeypox were HIVpositive in CDC report. Health Care (Don Mills), 2022.

O’Shea, J.; Filardo, T.D.; Morris, S.B.; Weiser, J.; Petersen, B.; Brooks, J.T. Interim guidance for prevention and treatment of monkeypox in persons with HIV Infection — United States, August 2022. MMWR Morb. Mortal. Wkly. Rep., 2022, 71(32), 1023-1028.
[http://dx.doi.org/10.15585/mmwr.mm7132e4] [PMID: 35951495]

Thornhill, J.P.; Barkati, S.; Walmsley, S.; Rockstroh, J.; Antinori, A.; Harrison, L.B.; Palich, R.; Nori, A.; Reeves, I.; Habibi, M.S.; Apea, V.; Boesecke, C.; Vandekerckhove, L.; Yakubovsky, M.; Sendagorta, E.; Blanco, J.L.; Florence, E.; Moschese, D.; Maltez, F.M.; Goorhuis, A.; Pourcher, V.; Migaud, P.; Noe, S.; Pintado, C.; Maggi, F.; Hansen, A.B.E.; Hoffmann, C.; Lezama, J.I.; Mussini, C.; Cattelan, A.; Makofane, K.; Tan, D.; Nozza, S.; Nemeth, J.; Klein, M.B.; Orkin, C.M. Monkeypox virus infection in humans across 16 Countries — April–June 2022. N. Engl. J. Med., 2022, 387(8), 679-691.
[http://dx.doi.org/10.1056/NEJMoa2207323] [PMID: 35866746]

Huang, S.T.; Wu, Y.H.; Lin, H.H.; Yang, J.Y.; Hsieh, P.Y.; Chiang, S.J.; Wang, S.P.; Chan, Y.H.; Lin, L.F.; Chen, Y.J.; Tsai, H.C.; Chen, Y.S.; Lee, S.S. The first imported case of monkeypox in Taiwan. J. Formos. Med. Assoc., 2022, 26, S0929-S6646.
[PMID: 36175217]

Nolasco, S; Vitale, F; Geremia, A; Tramuto, F; Maida, CM; Sciuto, A; Coco, C; Manuele, R; Frasca, E; Frasca, M; Magliocco, S; Gennaro, A; Tumino, E; Maresca, M; Montineri, A First case of monkeypox virus, SARS-CoV-2 and HIV co-infection. J. Infect., 2023, 86(1), e21-e23.
[http://dx.doi.org/10.1016/j.jinf.2022.08.014]

Vives, A.; Vantman, D.; Rocco, M.; Alonso-Tarres, C.; Castañe, E.R.; Cosentino, M. Coinfection of Monkeypox, COVID-19 and Syphilis in a PrEP using MSM: A case report from Barcelona. Res. Square, 2022.
[http://dx.doi.org/10.21203/rs.3.rs-1960471/v1]

Ahmad, S.; Pasha Km, M.; Raza, K.; Rafeeq, M.M.; Habib, A.H.; Eswaran, M.; Yadav, M.K. Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: An in-silico study. J. Biomol. Struct. Dyn., 2022, 22, 1-11.
[PMID: 35451934]

Jeyaraman, M.; Selvaraj, P.; Halesh, M.B.; Jeyaraman, N.; Nallakumarasamy, A.; Gupta, M.; Maffulli, N.; Gupta, A. Monkeypox: An emerging global public health emergency. Life (Basel), 2022, 12(10), 1590.
[http://dx.doi.org/10.3390/life12101590] [PMID: 36295025]

Lallogo, T.D.; Djigma, F.W.; Sorgho, P.A.; Martinson, J.J.; Compaore, T.R.; Traore, L.; Bado, P.; Bazie, B.V.E.J.T.; Amegnona, L.J.; Kagone, T.S.; Ouedraogo, R.A.; Ilboudo, D.P.; Obiri-Yeboah, D.; Yonli, A.T.; Simpore, J. KIR2DL5B and HLA DRB1*12 alleles seems to be associated with protection against HIV‐1 in serodiscordant couples in Burkina Faso. J. Med. Virol., 2022, 94(9), 4425-4432.
[http://dx.doi.org/10.1002/jmv.27821] [PMID: 35501290]

Meyer, H.; Ehmann, R.; Smith, G.L. Smallpox in the post-eradication era. Viruses, 2020, 12(2), 138.
[http://dx.doi.org/10.3390/v12020138] [PMID: 31991671]

Treatment information for healthcare professionals https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html

Rizk, J.G.; Lippi, G.; Henry, B.M.; Forthal, D.N.; Rizk, Y. Prevention and treatment of monkeypox. Drugs, 2022, 82(9), 957-963.
[http://dx.doi.org/10.1007/s40265-022-01742-y] [PMID: 35763248]

Berhanu, A.; Prigge, J.T.; Silvera, P.M.; Honeychurch, K.M.; Hruby, D.E.; Grosenbach, D.W. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection. Antimicrob. Agents Chemother., 2015, 59(7), 4296-4300.
[http://dx.doi.org/10.1128/AAC.00208-15] [PMID: 25896687]

Webb, E.; Rigby, I.; Michelen, M.; Dagens, A.; Cheng, V.; Rojek, A.M.; Dahmash, D.; Khader, S.; Gedela, K.; Norton, A.; Cevik, M.; Cai, E.; Harriss, E.; Lipworth, S.; Nartowski, R.; Groves, H.; Hart, P.; Blumberg, L.; Fletcher, T.; Jacob, S.T.; Sigfrid, L.; Horby, P.W. Availability, scope and quality of monkeypox clinical management guidelines globally: A systematic review. BMJ Glob. Health, 2022, 7(8), e009838.
[http://dx.doi.org/10.1136/bmjgh-2022-009838] [PMID: 35973747]

Mitjà, O; Ogoina, D; Titanji, BK; Galvan, C; Muyembe, JJ; Marks, M; Orkin, CM Monkeypox. Lancet, 2022, 401, 1-15.
[http://dx.doi.org/10.1016/S0140-6736(22)02075-X]

Elsayed, S.; Bondy, L.; Hanage, W.P. Monkeypox virus infections in humans. Clin. Microbiol. Rev., 2022, 35(4), e00092-22.
[http://dx.doi.org/10.1128/cmr.00092-22] [PMID: 36374082]

Sharma, K.; Akre, S.; Chakole, S.; Wanjari, M.B. Monkeypox: An emerging disease. Cureus, 2022, 14(9), e29393.
[PMID: 36304368]

Likos, A.M.; Sammons, S.A.; Olson, V.A.; Frace, A.M.; Li, Y.; Olsen-Rasmussen, M.; Davidson, W.; Galloway, R.; Khristova, M.L.; Reynolds, M.G.; Zhao, H.; Carroll, D.S.; Curns, A.; Formenty, P.; Esposito, J.J.; Regnery, R.L.; Damon, I.K. A tale of two clades: monkeypox viruses. J. Gen. Virol., 2005, 86(10), 2661-2672.
[http://dx.doi.org/10.1099/vir.0.81215-0] [PMID: 16186219]

Bunge, E.M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L.R.; Steffen, R. The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Negl. Trop. Dis., 2022, 16(2), e0010141.
[http://dx.doi.org/10.1371/journal.pntd.0010141] [PMID: 35148313]

Murugesu, J.A. Monkeypox threat could worsen. New Sci., 2022, 256(3408), 8.
[http://dx.doi.org/10.1016/S0262-4079(22)01835-8] [PMID: 36276923]

McCollum, A.M.; Damon, I.K. Human monkeypox. Clin. Infect. Dis., 2014, 58(2), 260-267.
[http://dx.doi.org/10.1093/cid/cit703] [PMID: 24158414]

Khodakevich, L.; Jezek, Z.; Messinger, D. Monkeypox virus: ecology and public health significance. Bull. World Health Organ., 1988, 66(6), 747-752.
[PMID: 2853010]

Leung, J.; McCollum, A.M.; Radford, K.; Hughes, C.; Lopez, A.S.; Guagliardo, S.A.J.; Nguete, B.; Likafi, T.; Kabamba, J.; Malekani, J.; Shongo Lushima, R.; Pukuta, E.; Karhemere, S.; Muyembe Tamfum, J.J.; Reynolds, M.G.; Wemakoy Okitolonda, E.; Schmid, D.S.; Marin, M. Varicella in tshuapa province, democratic republic of congo, 2009–2014. Trop. Med. Int. Health, 2019, 24(7), tmi.13243.
[http://dx.doi.org/10.1111/tmi.13243] [PMID: 31062445]

Dou, Y.M.; Yuan, H.; Tian, H.W. Monkeypox virus: past and present. World J. Pediatr., 2022, 10, 1-7.
[PMID: 36214966]

Gomez-Lucia, E. Monkeypox: Some keys to understand this emerging disease. Animals, 2022, 12(17), 2190.
[http://dx.doi.org/10.3390/ani12172190] [PMID: 36077910]

Durski, K.N.; McCollum, A.M.; Nakazawa, Y.; Petersen, B.W.; Reynolds, M.G.; Briand, S.; Djingarey, M.H.; Olson, V.; Damon, I.K.; Khalakdina, A. Emergence of monkeypox — West and Central Africa, 1970–2017. MMWR Morb. Mortal. Wkly. Rep., 2018, 67(10), 306-310.
[http://dx.doi.org/10.15585/mmwr.mm6710a5] [PMID: 29543790]

Mailhe, M; Beaumont, AL; Thy, M; Le Pluart, D; Perrineau, S; Houhou-Fidouh, N; Deconinck, L; Bertin, C; Ferré, VM; Cortier, M; De La Porte Des Vaux, C; Phung, BC; Mollo, B; Cresta, M; Bouscarat, F; Choquet, C; Descamps, D; Ghosn, J; Lescure, FX; Yazdanpanah, Y; Joly, V; Peiffer-Smadja, N Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study. Clin. Microbiol. Infect., 2023, 29(2), 269-271.

Technical Advisory Group on Human Monkeypox: report of a WHO meeting, Geneva, Switzerland, 11-12 January 1999 1999.http://www.who.int/gpsc/events/2008/afro_pledge_event/en/

Reed, K.D.; Melski, J.W.; Graham, M.B.; Regnery, R.L.; Sotir, M.J.; Wegner, M.V.; Kazmierczak, J.J.; Stratman, E.J.; Li, Y.; Fairley, J.A.; Swain, G.R.; Olson, V.A.; Sargent, E.K.; Kehl, S.C.; Frace, M.A.; Kline, R.; Foldy, S.L.; Davis, J.P.; Damon, I.K. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med., 2004, 350(4), 342-350.
[http://dx.doi.org/10.1056/NEJMoa032299] [PMID: 14736926]

Huhn, G.D.; Bauer, A.M.; Yorita, K.; Graham, M.B.; Sejvar, J.; Likos, A.; Damon, I.K.; Reynolds, M.G.; Kuehnert, M.J. Clinical characteristics of human monkeypox, and risk factors for severe disease. Clin. Infect. Dis., 2005, 41(12), 1742-1751.
[http://dx.doi.org/10.1086/498115] [PMID: 16288398]

Ogoina, D.; Iroezindu, M.; James, H.I.; Oladokun, R.; Yinka-Ogunleye, A.; Wakama, P.; Otike-odibi, B.; Usman, L.M.; Obazee, E.; Aruna, O.; Ihekweazu, C. Clinical course and outcome of human monkeypox in Nigeria. Clin. Infect. Dis., 2020, 71(8), e210-e214.
[http://dx.doi.org/10.1093/cid/ciaa143] [PMID: 32052029]

Hoffmann, C.; Jessen, H.; Wyen, C.; Grunwald, S.; Noe, S.; Teichmann, J.; Krauss, A.S.; Kolarikal, H.; Scholten, S.; Schuler, C.; Bickel, M.; Roll, C.; Kreckel, P.; Köppe, S.; Straub, M.; Klausen, G.; Lenz, J.; Esser, S.; Jensen, B.; Rausch, M.; Unger, S.; Pauli, R.; Härter, G.; Müller, M.; Masuhr, A.; Schäfer, G.; Seybold, U.; Schellberg, S.; Schneider, J.; Monin, M.B.; Wolf, E.; Spinner, C.D.; Boesecke, C. Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany. HIV Med., 2022. Epub ahead of print
[http://dx.doi.org/10.1111/hiv.13378] [PMID: 36059149]

Kuehn, B.M. Interim guidance for monkeypox among patients with HIV. JAMA, 2022, 328(12), 1173-1174.
[http://dx.doi.org/10.1001/jama.2022.14727] [PMID: 36166007]

Millman, A.J.; Denson, D.J.; Allen, M.L.; Malone, J.A.; Daskalakis, D.C.; Durrence, D.; Rustin, R.C.; Toomey, K.E.; Dabbs, T.; Dobard-Gary, F., III; Harton, P.E.; Hoffacker, L.; Lewis, H.; Lovett, S.; Crowder, D.; Vision, A.; Johnson, B.; Monroe, C.; O’Sullivan, L.; Valenciano, S.; Holland, D.P.; O’Neal, J.; Arona, A.; Freeman, D.; Sulka, A. A Health equity approach for implementation of JYNNEOS vaccination at large, community-based LGBTQIA+ Events — Georgia, August 27–September 5, 2022. MMWR Morb. Mortal. Wkly. Rep., 2022, 71(43), 1382-1883.
[http://dx.doi.org/10.15585/mmwr.mm7143e4] [PMID: 36301799]

Miller, M.J.; Cash-Goldwasser, S.; Marx, G.E.; Schrodt, C.A.; Kimball, A.; Padgett, K.; Noe, R.S.; McCormick, D.W.; Wong, J.M.; Labuda, S.M.; Borah, B.F.; Zulu, I.; Asif, A.; Kaur, G.; McNicholl, J.M.; Kourtis, A.; Tadros, A.; Reagan-Steiner, S.; Ritter, J.M.; Yu, Y.; Yu, P.; Clinton, R.; Parker, C.; Click, E.S.; Salzer, J.S.; McCollum, A.M.; Petersen, B.; Minhaj, F.S.; Brown, E.; Fischer, M.P.; Atmar, R.L.; DiNardo, A.R.; Xu, Y.; Brown, C.; Goodman, J.C.; Holloman, A.; Gallardo, J.; Siatecka, H.; Huffman, G.; Powell, J.; Alapat, P.; Sarkar, P.; Hanania, N.A.; Bruck, O.; Brass, S.D.; Mehta, A.; Dretler, A.W.; Feldpausch, A.; Pavlick, J.; Spencer, H.; Ghinai, I.; Black, S.R.; Hernandez-Guarin, L.N.; Won, S.Y.; Shankaran, S.; Simms, A.T.; Alarcón, J.; O’Shea, J.G.; Brooks, J.T.; McQuiston, J.; Honein, M.A.; O’Connor, S.M.; Chatham-Stephens, K.; O’Laughlin, K.; Rao, A.K.; Raizes, E.; Gold, J.A.W.; Morris, S.B.; Duessel, S.; Danaie, D.; Hickman, A.; Griffith, B.; Sanneh, H.; Hutchins, H.; Phyathep, C.; Carpenter, A.; Shelus, V.; Petras, J.; Hennessee, I.; Davis, M.; McArdle, C.; Dawson, P.; Gutelius, B.; Bisgard, K.; Wong, K.; Galang, R.R.; Perkins, K.M.; Filardo, T.D.; Davidson, W.; Hutson, C.; Lowe, D.; Zucker, J.E.; Wheeler, D.A.; He, L.; Jain, A.K.; Semeniuk, O.; Chatterji, D.; McClure, M.; Li, L.X.; Mata, J.; Beselman, S.; Cross, S.L.; Menzies, B.; Keller, M.; York, N.; Chaturvedi, V.; York, N.; Thet, A.; Carroll, R.; Hebert, C.; Patel, G.; Gandhi, V.; Abrams-Downey, A.; Nawab, M.; Landon, E.; Lee, G.; Kaplan-Lewis, E.; Miranda, C.; Carmack, A.E.; Traver, E.C.; Lazarte, S.; Perl, T.M.; Chow, J.; Kitchell, E.; Nijhawan, A.; Habib, O.; Bernus, A.; Andujar, G.; Davar, K.; Holtom, P.; Wald-Dickler, N.; Lorio, M.A.; Gaviria, J.; Chu, V.; Wolfe, C.R.; McKellar, M.S.; Farran, S.; Diaz Wong, R.A.; Schliep, T.; Shaw, R.; Tebas, P.; Richterman, A.; Aurelius, M.; Peterson, L.; Trible, R.; Rehman, T.; Sabzwari, R.; Hines, E., Jr; Birkey, T.; King, J.; Farabi, A.; Jenny-Avital, E.; Touleyrou, L.; Sandhu, A.; Newman, G.; Bhamidipati, D.; Bhamidipati, D.; Vigil, K.; Caro, M.; Banowski, K.; Chinyadza, T.W.; Rosenzweig, J.; Jones, M.S.; Camargo, J.F.; Marsh, K.J.; Liu, E.W.; Guerrero-Wooley, R.; Pottinger, P. Severe monkeypox in hospitalized patients — United States, August 10–October 10, 2022. MMWR Morb. Mortal. Wkly. Rep., 2022, 71(44), 1412-1417.
[http://dx.doi.org/10.15585/mmwr.mm7144e1] [PMID: 36327164]

Clinical considerations for treatment and prophylaxis of mpox infection in people who are immunocompromised 2023.https://www.cdc.gov/poxvirus/monkeypox/clinicians/people-with-HIV.html

Khani, E.; Afsharirad, B.; Entezari-Maleki, T. Monkeypox treatment: Current evidence and future perspectives. J. Med. Virol., 2023, 95(1), e28229.
[http://dx.doi.org/10.1002/jmv.28229] [PMID: 36253931]

Stern, A.; Alonso, C.D.; Garcia-Vidal, C.; Cardozo, C.; Slavin, M.; Yong, M.K.; Ho, S.A.; Mehta Steinke, S.; Avery, R.K.; Koehler, P.; Scheid, C.; Cornely, O.A.; Maertens, J.; Abi Aad, Y.; Epstein, D.J.; Papanicolaou, G.A.; Neofytos, D. Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: A retrospective multicentre cohort study. J. Antimicrob. Chemother., 2021, 76(11), 3020-3028.
[http://dx.doi.org/10.1093/jac/dkab259] [PMID: 34324678]

Baker, R.O.; Bray, M.; Huggins, J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res., 2003, 57(1-2), 13-23.
[http://dx.doi.org/10.1016/S0166-3542(02)00196-1] [PMID: 12615299]

Fabrizio, C.; Bruno, G.; Cristiano, L.; Buccoliero, G.B. Cidofovir for treating complicated monkeypox in a man with acquired immune deficiency syndrome. Infection, 2023, 51(2), 519-522.
[http://dx.doi.org/10.1007/s15010-022-01949-x] [PMID: 36355271]

Dodge, M.J.; MacNeil, K.M.; Tessier, T.M.; Weinberg, J.B.; Mymryk, J.S. Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies. Antiviral Res., 2021, 188, 105034.
[http://dx.doi.org/10.1016/j.antiviral.2021.105034] [PMID: 33577808]

Alcamo, A.M.; Wolf, M.S.; Alessi, L.J.; Chong, H.J.; Green, M.; Williams, J.V.; Simon, D.W. Successful use of cidofovir in an immuno-competent child with severe adenoviral sepsis. Pediatrics, 2020, 145(1), e20191632.
[http://dx.doi.org/10.1542/peds.2019-1632] [PMID: 31826930]

Cidofovir generic name and formulations 2023. Available from: https://www.empr.com/drug/cidofovir/

Smallpox preparedness and response updates from FDA 2023. https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda

El Helou, G.; Razonable, R.R. Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. Expert Opin. Drug Saf., 2019, 18(11), 1017-1030.
[http://dx.doi.org/10.1080/14740338.2019.1662787] [PMID: 31478398]

Lea, A.P.; Bryson, H.M. Cidofovir. Drugs, 1996, 52(2), 225-230.
[http://dx.doi.org/10.2165/00003495-199652020-00006] [PMID: 8841740]

Chamberlain, J.M.; Sortino, K.; Sethna, P.; Bae, A.; Lanier, R.; Bambara, R.A.; Dewhurst, S. Cidofovir diphosphate inhibits adenovirus 5 dna polymerase via both nonobligate chain termination and direct inhibition, and polymerase mutations confer cidofovir resistance on intact virus. Antimicrob. Agents Chemother., 2018, 63(1), e01925-e18.
[PMID: 30397065]

Bua, G.; Conti, I.; Manaresi, E.; Sethna, P.; Foster, S.; Bonvicini, F.; Gallinella, G. Antiviral activity of brincidofovir on parvovirus B19. Antiviral Res., 2019, 162, 22-29.

Adler, H.; Gould, S.; Hine, P.; Snell, L.B.; Wong, W.; Houlihan, C.F.; Osborne, J.C.; Rampling, T.; Beadsworth, M.B.J.; Duncan, C.J.A.; Dunning, J.; Fletcher, T.E.; Hunter, E.R.; Jacobs, M.; Khoo, S.H.; Newsholme, W.; Porter, D.; Porter, R.J.; Ratcliffe, L.; Schmid, M.L.; Semple, M.G.; Tunbridge, A.J.; Wingfield, T.; Price, N.M.; Abouyannis, M.; Al-Balushi, A.; Aston, S.; Ball, R.; Beeching, N.J.; Blanchard, T.J.; Carlin, F.; Davies, G.; Gillespie, A.; Hicks, S.R.; Hoyle, M-C.; Ilozue, C.; Mair, L.; Marshall, S.; Neary, A.; Nsutebu, E.; Parker, S.; Ryan, H.; Turtle, L.; Smith, C.; van Aartsen, J.; Walker, N.F.; Woolley, S.; Chawla, A.; Hart, I.; Smielewska, A.; Joekes, E.; Benson, C.; Brindley, C.; Das, U.; Eyton-Chong, C.K.; Gnanalingham, C.; Halfhide, C.; Larru, B.; Mayell, S.; McBride, J.; Oliver, C.; Paul, P.; Riordan, A.; Sridhar, L.; Storey, M.; Abdul, A.; Abrahamsen, J.; Athan, B.; Bhagani, S.; Brown, C.S.; Carpenter, O.; Cropley, I.; Frost, K.; Hopkins, S.; Joyce, J.; Lamb, L.; Lyons, A.; Mahungu, T.; Mepham, S.; Mukwaira, E.; Rodger, A.; Taylor, C.; Warren, S.; Williams, A.; Levitt, D.; Allen, D.; Dix-on, J.; Evans, A.; McNicholas, P.; Payne, B.; Price, D.A.; Schwab, U.; Sykes, A.; Taha, Y.; Ward, M.; Emonts, M.; Owens, S.; Botgros, A.; Douthwaite, S.T.; Goodman, A.; Luintel, A.; MacMahon, E.; Nebbia, G.; O’Hara, G.; Parsons, J.; Sen, A.; Stevenson, D.; Sullivan, T.; Taj, U.; van Nipsen tot Pannerden, C.; Winslow, H.; Zatyka, E.; Alozie-Otuka, E.; Beviz, C.; Ceesay, Y.; Gargee, L.; Kabia, M.; Mitchell, H.; Perkins, S.; Sasson, M.; Sehmbey, K.; Tabios, F.; Wigglesworth, N.; Aarons, E.J.; Brooks, T.; Dryden, M.; Furneaux, J.; Gibney, B.; Small, J.; Truelove, E.; Warrell, C.E.; Firth, R.; Hobson, G.; Johnson, C.; Dewynter, A.; Nixon, S.; Spence, O.; Bugert, J.J.; Hruby, D.E. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect. Dis., 2022, 22(8), 1153-1162.
[http://dx.doi.org/10.1016/S1473-3099(22)00228-6] [PMID: 35623380]

Tecovirimat 2022. Available from: https://elsevier.health/en-US/preview/tecovirimat=

Yang, G.; Pevear, D.C.; Davies, M.H.; Collett, M.S.; Bailey, T.; Rippen, S.; Barone, L.; Burns, C.; Rhodes, G.; Tohan, S.; Huggins, J.W.; Baker, R.O.; Buller, R.L.M.; Touchette, E.; Waller, K.; Schriewer, J.; Neyts, J.; DeClercq, E.; Jones, K.; Hruby, D.; Jordan, R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol., 2005, 79(20), 13139-13149.
[http://dx.doi.org/10.1128/JVI.79.20.13139-13149.2005] [PMID: 16189015]

Quenelle, D.C.; Buller, R.M.L.; Parker, S.; Keith, K.A.; Hruby, D.E.; Jordan, R.; Kern, E.R. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother., 2007, 51(2), 689-695.
[http://dx.doi.org/10.1128/AAC.00879-06] [PMID: 17116683]

Jordan, R.; Goff, A.; Frimm, A.; Corrado, M.L.; Hensley, L.E.; Byrd, C.M.; Mucker, E.; Shamblin, J.; Bolken, T.C.; Wlazlowski, C.; Johnson, W.; Chapman, J.; Twenhafel, N.; Tyavanagimatt, S.; Amantana, A.; Chinsangaram, J.; Hruby, D.E.; Huggins, J. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother., 2009, 53(5), 1817-1822.
[http://dx.doi.org/10.1128/AAC.01596-08] [PMID: 19223621]

Mucker, E.M.; Goff, A.J.; Shamblin, J.D.; Grosenbach, D.W.; Damon, I.K.; Mehal, J.M.; Holman, R.C.; Carroll, D.; Gallardo, N.; Olson, V.A.; Clemmons, C.J.; Hudson, P.; Hruby, D.E. Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox). Antimicrob. Agents Chemother., 2013, 57(12), 6246-6253.
[http://dx.doi.org/10.1128/AAC.00977-13] [PMID: 24100494]

Russo, A.T.; Berhanu, A.; Bigger, C.B.; Prigge, J.; Silvera, P.M.; Grosenbach, D.W.; Hruby, D. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine, 2020, 38(3), 644-654.
[http://dx.doi.org/10.1016/j.vaccine.2019.10.049] [PMID: 31677948]

Grosenbach, D.W.; Honeychurch, K.; Rose, E.A.; Chinsangaram, J.; Frimm, A.; Maiti, B.; Lovejoy, C.; Meara, I.; Long, P.; Hruby, D.E. Oral Tecovirimat for the treatment of smallpox. N. Engl. J. Med., 2018, 379(1), 44-53.
[http://dx.doi.org/10.1056/NEJMoa1705688] [PMID: 29972742]

Laudisoit, A.; Tepage, F.; Colebunders, R. Oral Tecovirimat for the treatment of smallpox. N. Engl. J. Med., 2018, 379(21), 2084-2085.
[http://dx.doi.org/10.1056/NEJMc1811044] [PMID: 30462945]

2018.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf

Russo, A.T.; Grosenbach, D.W.; Chinsangaram, J.; Honeychurch, K.M.; Long, P.G.; Lovejoy, C.; Maiti, B.; Meara, I.; Hruby, D.E. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev. Anti Infect. Ther., 2021, 19(3), 331-344.
[http://dx.doi.org/10.1080/14787210.2020.1819791] [PMID: 32882158]

Highlights of prescribing information 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214518s000lbl.pdf

Shen, Y.; Shi, Z.; Yan, B. Carboxylesterases: Pharmacological inhibition, regulated expression and transcriptional involvement of nuclear receptors and other transcription factors. Nucl. Receptor Res., 2019, 6, 101435.
[http://dx.doi.org/10.32527/2019/101435]

NDA approval – animal efficacy 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208627Orig1s000ltr.PDF=

Top, H. 2020.https://www.statista.com/statistics/273434/revenue-of-the-worlds-most-important-aids-drugs/

Bianco, M.C.A.D.; Inacio Leite, D.; Silva Castelo Branco, F.; Boechat, N.; Uliassi, E.; Bolognesi, M.L.; Bastos, M.M. The use of Zidovudine pharmacophore in multi-target-directed ligands for AIDS therapy. Molecules, 2022, 27(23), 8502.
[http://dx.doi.org/10.3390/molecules27238502] [PMID: 36500608]

Complete Regimens 2023.. 2022. https://www.poz.com/drugs/classes/complete-regimens

Ayele, A.G.; Enyew, E.F.; Kifle, Z.D. Roles of existing drug and drug targets for COVID-19 management. Metabolism Open, 2021, 11, 100103.
[http://dx.doi.org/10.1016/j.metop.2021.100103] [PMID: 34222852]

Zhou, Y.W.; Xie, Y.; Tang, L.S.; Pu, D.; Zhu, Y.J.; Liu, J.Y.; Ma, X.L. Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduct. Target. Ther., 2021, 6(1), 317.
[http://dx.doi.org/10.1038/s41392-021-00733-x] [PMID: 34446699]

Shen, Y.; Eades, W.; Yan, B. The COVID‐19 medicine remdesivir is therapeutically activated by carboxylesterase‐1, and excessive hydrolysis increases cytotoxicity. Hepatol. Commun., 2021, 5(9), 1622-1623.
[http://dx.doi.org/10.1002/hep4.1736] [PMID: 34510834]

Shen, Y.; Eades, W.; Yan, B. Remdesivir potently inhibits carboxylesterase‐2 through covalent modifications: Signifying strong drug‐drug interactions. Fundam. Clin. Pharmacol., 2021, 35(2), 432-434.
[http://dx.doi.org/10.1111/fcp.12643] [PMID: 33369768]

Shen, Y.; Eades, W.; Liu, W.; Yan, B. The COVID-19 oral drug molnupiravir is a ces2 substrate: Potential drug-drug interactions and impact of ces2 genetic polymorphism in vitro. Drug Metab. Dispos., 2022, 50(9), 1151-1160.
[http://dx.doi.org/10.1124/dmd.122.000918] [PMID: 35790245]

Liu, W.; Yu, S.; Yan, B. Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus. Biochem. Pharmacol., 2022, 204, 115224.
[http://dx.doi.org/10.1016/j.bcp.2022.115224] [PMID: 36007574]

Ito, S.; Hirota, T.; Yanai, M.; Muto, M.; Watanabe, E.; Taya, Y.; Ieiri, I. Effects of genetic polymorphisms of cathepsin A on metabolism of Tenofovir Alafenamide. Genes, 2021, 12(12), 2026.
[http://dx.doi.org/10.3390/genes12122026] [PMID: 34946974]

Li, R.; Liclican, A.; Xu, Y.; Pitts, J.; Niu, C.; Zhang, J.; Kim, C.; Zhao, X.; Soohoo, D.; Babusis, D.; Yue, Q.; Ma, B.; Murray, B.P.; Subramanian, R.; Xie, X.; Zou, J.; Bilello, J.P.; Li, L.; Schultz, B.E.; Sakowicz, R.; Smith, B.J.; Shi, P.Y.; Murakami, E.; Feng, J.Y. Key metabolic enzymes involved in remdesivir activation in human lung cells. Antimicrob. Agents Chemother., 2021, 65(9), e00602-21.
[http://dx.doi.org/10.1128/AAC.00602-21] [PMID: 34125594]

Yan, B.; Eades, W.; Liu, W.; Shen, Y.; Shi, Z. Covalent CES2 inhibitors protect against reduced formation of intestinal organoids by the anticancer drug irinotecan. Curr. Drug Metab., 2022, 23(12), 1000-1010. Epub ahead of print
[http://dx.doi.org/10.2174/1389200224666221212143904] [PMID: 36515038]

Yan, D.; Ra, O.H.; Yan, B. The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. Animal Diseases, 2021, 1(1), 15.
[http://dx.doi.org/10.1186/s44149-021-00017-5] [PMID: 34778881]

Yan, D.; Yan, B. Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. Fundam. Clin. Pharmacol., 2023, 2023, fcp.12889.. Epub ahead of print
[http://dx.doi.org/10.1111/fcp.12889] [PMID: 36931725]

Singh, R.S.P.; Walker, G.S.; Kadar, E.P.; Cox, L.M.; Eng, H.; Sharma, R.; Bergman, A.J.; Van Eyck, L.; Hackman, F.; Toussi, S.S.; Kalgutkar, A.S.; Obach, R.S. Metabolism and excretion of nirmatrelvir in humans using quantitative fluorine nuclear magnetic resonance spectroscopy: A novel approach for accelerating drug development. Clin. Pharmacol. Ther., 2022, 112(6), 1201-1206.
[http://dx.doi.org/10.1002/cpt.2683] [PMID: 35678736]

Mirza, A.Z. Advancement in the development of heterocyclic nucleosides for the treatment of cancer - A review. Nucleosides Nucleotides Nucleic Acids, 2019, 38(11), 836-857.
[http://dx.doi.org/10.1080/15257770.2019.1615623] [PMID: 31135268]

Dantsu, Y.; Zhang, Y.; Zhang, W. Advances in therapeutic] L-nucleosides and L-nucleic acids with unusual handedness. Genes, 2021, 13(1), 46.
[http://dx.doi.org/10.3390/genes13010046] [PMID: 35052385]

Ramesh, D.; Vijayakumar, B.G.; Kannan, T. Advances in nucleoside and nucleotide analogues in tackling human immunodeficiency virus and hepatitis virus infections. Chem. Med. Chem., 2021, 16(9), 1403-1419.
[http://dx.doi.org/10.1002/cmdc.202000849] [PMID: 33427377]

Jornada, D.; dos Santos Fernandes, G.; Chiba, D.; de Melo, T.; dos Santos, J.; Chung, M. The prodrug approach: A successful tool for improving drug solubility. Molecules, 2015, 21(1), 42.
[http://dx.doi.org/10.3390/molecules21010042] [PMID: 26729077]

Cihlar, T.; Chen, M.S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol., 1996, 50(6), 1502-1510.
[PMID: 8967971]

Lade, J.M.; To, E.E.; Hendrix, C.W.; Bumpus, N.N. Discovery of genetic variants of the kinases that activate tenofovir in a compartment-specific manner. EBioMedicine, 2015, 2(9), 1145-1152.
[http://dx.doi.org/10.1016/j.ebiom.2015.07.008] [PMID: 26501112]

Iannuzzi, S.; von Kleist, M. Mathematical modelling of the molecular mechanisms of interaction of tenofovir with emtricitabine against HIV. Viruses, 2021, 13(7), 1354.
[http://dx.doi.org/10.3390/v13071354] [PMID: 34372560]

Lash, L.H.; Lee, C.A.; Wilker, C.; Shah, V. Transporter-dependent cytotoxicity of antiviral drugs in primary cultures of human proximal tubular cells. Toxicology, 2018, 404-405, 10-24.
[http://dx.doi.org/10.1016/j.tox.2018.05.002] [PMID: 29738843]

Kumar, D.; Trivedi, N. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. Biomed. Pharmacother., 2021, 139, 111642.
[http://dx.doi.org/10.1016/j.biopha.2021.111642] [PMID: 33940506]

Nwabufo, C.K.; Bendayan, R. Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs. Trends Pharmacol. Sci., 2022, 43(12), 1041-1054.
[http://dx.doi.org/10.1016/j.tips.2022.09.005] [PMID: 36374805]

Giacomini, K.M.; Yee, S.W.; Koleske, M.L.; Zou, L.; Matsson, P.; Chen, E.C.; Kroetz, D.L.; Miller, M.A.; Gozalpour, E.; Chu, X. New and emerging research on solute carrier and ATP binding cassette transporters in drug discovery and development: Outlook from the international transporter consortium. Clin. Pharmacol. Ther., 2022, 112(3), 540-561.
[http://dx.doi.org/10.1002/cpt.2627] [PMID: 35488474]

Cihlar, T.; Ho, E.S.; Lin, D.C.; Mulato, A.S. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids, 2001, 20(4-7), 641-648.
[http://dx.doi.org/10.1081/NCN-100002341] [PMID: 11563082]

Tippin, T.K.; Morrison, M.E.; Brundage, T.M.; Momméja-Marin, H. Brincidofovir is not a substrate for the human organic anion transporter 1: A mechanistic explanation for the lack of nephrotoxicity observed in clinical studies. Ther. Drug Monit., 2016, 38(6), 777-786.
[http://dx.doi.org/10.1097/FTD.0000000000000353] [PMID: 27851688]

Chan, L.; Asriel, B.; Eaton, E.F.; Wyatt, C.M. Potential kidney toxicity from the antiviral drug tenofovir. Curr. Opin. Nephrol. Hypertens., 2018, 27(2), 102-112.
[http://dx.doi.org/10.1097/MNH.0000000000000392] [PMID: 29278542]

Obiebi, I.P.; Nwannadi, E.A. Tenofovir-induced renal tubular dysfunction among human immunodeficiency virus patients on antiretroviral therapy in Nigeria: Prospects for early detection of presymptomatic nephrotoxicity. Kidney Res. Clin. Pract., 2018, 37(3), 230-238.
[http://dx.doi.org/10.23876/j.krcp.2018.37.3.230] [PMID: 30254847]

Weiss, J.; Rose, J.; Storch, C.H.; Ketabi-Kiyanvash, N.; Sauer, A.; Haefeli, W.E.; Efferth, T. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother., 2006, 59(2), 238-245.
[http://dx.doi.org/10.1093/jac/dkl474] [PMID: 17202245]

Moss, D.M.; Neary, M.; Owen, A. The role of drug transporters in the kidney: lessons from tenofovir. Front. Pharmacol., 2014, 5, 248.
[http://dx.doi.org/10.3389/fphar.2014.00248] [PMID: 25426075]

Zondo, N.M.; Sobia, P.; Sivro, A.; Ngcapu, S.; Ramsuran, V.; Archary, D. Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV. Front. Genet., 2022, 13, 940661.
[http://dx.doi.org/10.3389/fgene.2022.940661] [PMID: 36246609]